Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
Healthcare | Drug Manufacturers - Major | USA
financial highlights | statements
IndexDJIA S&P500 P/E22.93 EPS (ttm)1.72 Insider Own0.10% Shs Outstand5.62B Perf Week-6.34%
Market Cap221.63B Forward P/E12.88 EPS next Y3.06 Insider Trans-13.61% Shs Float5.55B Perf Month-5.81%
Income10.35B PEG4.17 EPS next Q0.75 Inst Own76.40% Short Float1.44% Perf Quarter-6.74%
Sales53.65B P/S4.13 EPS this Y-11.90% Inst Trans-0.23% Short Ratio3.24 Perf Half Y-10.41%
Book/sh10.95 P/B3.60 EPS next Y6.03% ROA6.80% Target Price44.36 Perf Year7.62%
Cash/sh3.35 P/C11.77 EPS next 5Y5.50% ROE16.20% 52W Range34.37 - 46.47 Perf YTD-9.69%
Dividend1.44 P/FCF38.17 EPS past 5Y1.00% ROI10.20% 52W High-15.17% Beta0.71
Dividend %3.65% Quick Ratio1.30 Sales past 5Y0.80% Gross Margin79.30% 52W Low14.69% ATR0.78
Employees92400 Current Ratio1.60 Sales Q/Q2.00% Oper. Margin22.80% RSI (14)29.64 Volatility3.07% 1.62%
OptionableYes Debt/Eq0.66 EPS Q/Q-143.40% Profit Margin20.80% Rel Volume1.03 Prev Close38.98
ShortableYes LT Debt/Eq0.52 EarningsApr 30 BMO Payout72.00% Avg Volume24.64M Price39.42
Recom2.50 SMA20-6.07% SMA50-6.39% SMA200-6.62% Volume25,256,358 Change1.13%
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Nov-01-18Downgrade BMO Capital Markets Outperform → Market Perform
Jun-08-18Initiated Cantor Fitzgerald Overweight $45
Apr-05-18Downgrade Barclays Overweight → Equal Weight $41 → $38
Jan-29-18Reiterated SunTrust Hold $33 → $40
Sep-20-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-24-19 12:00AM  AstraZeneca chief claims vindication five years after Pfizer bid Financial Times
Apr-23-19 05:32PM  6 Poorly Performing Stocks in Gurus' Portfolios GuruFocus.com
03:54PM  Kidney-Cancer Market: Good for Patients, Hard for Investors Motley Fool
11:09AM  Why Is Bristol-Myers Near 52-Week Lows? InvestorPlace
10:59AM  Amgen (AMGN) to Report Q1 Earnings: What's in the Cards? Zacks
10:32AM  Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks
09:46AM  Alexion (ALXN) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-22-19 05:34PM  Exact Sciences Is Near an All-Time High: Here's Why It Could Go Even Higher Motley Fool
04:42PM  What's in Store for Bayer (BAYRY) This Earnings Season? Zacks
11:08AM  Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? Zacks
10:24AM  Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns Benzinga
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
09:28AM  Mondays Vital Data: Pfizer, Canopy Growth Corp and Microsoft InvestorPlace
07:37AM  Merck's Keytruda wins FDA approval as combination therapy for kidney cancer Reuters
06:59AM  Merck's Keytruda wins FDA approval as combination therapy for kidney cancer Reuters
05:55AM  Pfizer Stock Suffers From an Underappreciated Drugs Pipeline InvestorPlace
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
Apr-18-19 11:12PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
06:37PM  Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study MarketWatch
06:14PM  Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study Reuters
05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
05:25PM  Worsening Health-Care Rout Wipes Out $150 Billion in Four Days Bloomberg
05:05PM  Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis Business Wire
05:00PM  Pharmaceutical ETFs Catch Healthcare Contagion ETF Trends
03:17PM  Health-care drama has now spread to biopharma stocks MarketWatch
02:00PM  Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders Business Wire
12:03PM  Markets Right Now: Stocks waver in midday trading Associated Press
11:29AM  Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks
10:59AM  Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks
10:22AM  Here Are the Key Takeaways From J&J's Q1 Earnings Report Zacks
Apr-17-19 11:10AM  Wave Life Sciences Plunges After DMD Study Data Readout Zacks
09:52AM  Pfizer Falls 3% Investing.com
Apr-16-19 03:31PM  5 Healthcare Stocks to Watch If America Chooses a Single-Payer System InvestorPlace
10:58AM  J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View Zacks
Apr-15-19 04:06PM  These 2 health-care giants could take down the ETFs in their sector, says investor CNBC
03:00PM  Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
10:07AM  J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer Zacks
Apr-14-19 07:00AM  The 3 Greatest Risks Pfizer Faces Motley Fool
Apr-13-19 04:00AM  Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older Business Wire
Apr-12-19 09:55AM  Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall Zacks
09:42AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
09:20AM  Forward Guidance Will Make or Break JNJ Earnings InvestorPlace
Apr-11-19 03:33PM  Biotechnology Market on a Tear: 5 ETFs in Spotlight Zacks
02:57PM  What Medicare for All would do to the health-care sector MarketWatch
08:25AM  Brexit: What it means for U.S. banks, car makers, drug companies MarketWatch
07:30AM  A Giant U.K. Pension Fund Is Making Big Bets on Verizon, Home Depot, J&J, and Mastercard Stock Barrons.com
Apr-10-19 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
03:24PM  Here's what to expect from the stock market next month Investopedia
07:13AM  Who Has Been Selling Pfizer Inc. (NYSE:PFE) Shares? Simply Wall St.
Apr-09-19 08:02AM  Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients Zacks
Apr-08-19 10:37AM  Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym Zacks
09:41AM  The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca Zacks
Apr-07-19 04:32PM  Bulls & Bears Of The Week: Dow, Lyft, Pfizer, Schlumberger, Tesla And More Benzinga
12:49PM  Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy? TheStreet.com
Apr-06-19 03:41AM  Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks
Apr-05-19 09:26PM  Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks
10:20AM  Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks
09:17AM  Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval Zacks
Apr-04-19 05:45PM  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Zacks
02:57PM  U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer Business Wire
11:30AM  U.S., China key to GSK's consumer venture with Pfizer Reuters
10:45AM  U.S., China key to GSK's consumer venture with Pfizer Reuters
10:26AM  Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval Zacks
10:04AM  AM Best Affirms Credit Ratings of Blue Whale Re Ltd. Business Wire
09:41AM  The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone Zacks
Apr-03-19 02:51PM  Top Research Reports for Pfizer, Royal Dutch Shell & Celgene Zacks
10:15AM  Sangamo Rises on Positive Phase I/II Hemophilia Study Data Zacks
10:10AM  Why the Earnings Surprise Streak Could Continue for Pfizer (PFE) Zacks
09:42AM  VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer Business Wire
07:37AM  3 Big Stock Charts for Wednesday: Twitter, Western Union and Wynn Resorts InvestorPlace
04:41AM  Micron Technology, Tencent and two dozen other companies most likely to benefit from a China trade deal MarketWatch
Apr-02-19 04:17PM  Gene-Focused Biotechs Pop After Pfizer Partner Scores In Hemophilia A Investor's Business Daily
12:47PM  Sangamo Soars Amid Multiple Development Pipeline Updates Benzinga
11:58AM  3 Healthcare Stocks to Trade Now InvestorPlace
11:33AM  Why Sangamo Therapeutics Stock Is Soaring Today Motley Fool
09:55AM  Sangamo Stock Soars on Positive Hemophilia Treatment Trial TheStreet.com
08:10AM  Sangamo's stock soars after upbeat trial data for hemophilia treatment MarketWatch
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy PR Newswire
07:00AM  Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy Business Wire
Apr-01-19 04:57PM  Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics Zacks
04:00PM  Spero Gets Fast Track Designation for SPR994, Shares Improve Zacks
01:03PM  Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts Benzinga
06:00AM  Saratoga Springs communications firm growing a year after private-equity acquisition American City Business Journals
Mar-29-19 06:04PM  This Dow stock could be a way to play catch-up to the rally CNBC
04:41PM  These Are The 5 Worst Dow Jones Stocks Of Q1 Investor's Business Daily
03:23PM  Wall Street is buzzing about Gileads rheumatoid arthritis drug. Heres why MarketWatch
Mar-28-19 09:52AM  One Key Strategy to Build Your Ultimate Retirement Portfolio InvestorPlace
08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
07:41AM  3 Big Stock Charts for Thursday: Pfizer, Coty and Pioneer Natural Resources InvestorPlace
Mar-27-19 05:45PM  Pfizer (PFE) Dips More Than Broader Markets: What You Should Know Zacks
05:39PM  Calithera (CALA) Initiates Phase I/II Study of Telaglenastat Zacks
04:02PM  6 Stocks With High Dividend Yields GuruFocus.com
12:45PM  6 Gene Therapy M&A Targets On The Radar Benzinga
10:25AM  Pfizer Stock Will Gain Because Its Pipeline Has Promise, Analyst Says Barrons.com
Mar-26-19 05:32PM  Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote American City Business Journals
12:46PM  Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action Benzinga
11:18AM  AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan Zacks
Mar-25-19 06:11PM  Were Hedge Funds Right About Pfizer Inc. (PFE)? Insider Monkey
02:45PM  Ascendis Pivotal Growth Hormone Deficiency Study Data Positive Zacks
10:53AM  S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion PR Newswire
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKENZIE ALEXANDER RExecutive Vice PresidentApr 01Sale42.8315,000642,503110,094Apr 02 03:05 PM
JOHNSON RADY AExecutive Vice PresidentMar 15Sale41.138,700357,83159,797Mar 18 06:37 PM
READ IAN CExecutive ChairmanMar 04Sale43.2950,7882,198,4741,639,280Mar 06 04:03 PM
READ IAN CExecutive ChairmanMar 04Sale43.17530,07822,882,7021,109,202Mar 06 04:03 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale43.268,725377,444172,094Mar 06 03:29 PM
SUSMAN SALLYExecutive Vice PresidentMar 04Sale43.1463,9982,760,698108,096Mar 06 03:29 PM
Dolsten MikaelPresident R&DMar 04Sale43.5249,0822,136,293289,126Mar 05 04:54 PM
ROGERS DAWNExecutive Vice PresidentMar 04Sale42.9815,002644,79814,920Mar 05 04:55 PM
Dolsten MikaelPresident R&DMar 01Option Exercise31.34106,1913,328,057438,679Mar 05 04:54 PM
Dolsten MikaelPresident R&DMar 01Sale43.56100,4714,376,852338,208Mar 05 04:54 PM
ROGERS DAWNExecutive Vice PresidentFeb 27Option Exercise32.2319,297621,94245,049Mar 01 07:47 PM
SUSMAN SALLYExecutive Vice PresidentFeb 27Option Exercise32.2385,7632,764,141228,743Mar 01 07:47 PM
YOUNG JOHN DGroup PresidentFeb 27Option Exercise32.23154,3744,975,474441,923Mar 01 07:47 PM
GOETTLER MICHAELGroup PresidentFeb 27Option Exercise32.2330,017967,44848,652Mar 01 07:37 PM
Hwang AngelaGroup PresidentFeb 27Option Exercise32.2311,792380,05623,635Mar 01 07:37 PM
JOHNSON RADY AExecutive Vice PresidentFeb 27Option Exercise32.2330,017967,44881,341Mar 01 07:37 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 27Option Exercise32.2364,3222,073,098123,145Mar 01 07:37 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 27Option Exercise32.2381,4752,625,939416,278Mar 01 07:37 PM
BOURLA ALBERTChief Executive OfficerFeb 27Option Exercise32.2364,3222,073,098331,982Mar 01 07:29 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 27Option Exercise32.2325,729829,246121,743Mar 01 07:29 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 27Option Exercise32.23182,2475,873,821588,177Mar 01 07:29 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0343,724919,516312,403Feb 26 07:45 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0318,004378,62461,182Feb 26 07:45 PM
BOURLA ALBERTChief Executive OfficerFeb 23Option Exercise21.0336,008757,248191,438Feb 26 07:45 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.0387,4491,839,052388,024Feb 26 07:45 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03185,1853,894,441522,576Feb 26 07:45 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.0397,7372,055,409205,833Feb 26 07:46 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0343,724919,51683,781Feb 26 07:45 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentFeb 23Option Exercise21.0341,615875,163144,164Feb 26 07:10 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0330,864649,070115,139Feb 26 07:10 PM
ROGERS DAWNExecutive Vice PresidentFeb 23Option Exercise21.0319,290405,66937,638Feb 26 07:10 PM
GOETTLER MICHAELGroup PresidentFeb 23Option Exercise21.0319,290405,66931,507Feb 26 07:11 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 01Sale42.755,000213,75040,057Feb 01 07:21 PM
Dolsten MikaelPresident R&DJan 31Option Exercise29.78125,9683,751,425362,051Feb 01 07:28 PM
LANKLER DOUGLAS MExecutive Vice PresidentJan 30Sale41.1938,8001,598,07145,057Feb 01 07:21 PM
READ IAN CChairman & CEONov 02Option Exercise26.641,100,20129,312,5881,760,958Nov 06 03:46 PM
PFIZER INC10% OwnerOct 15Buy18.0055,5561,000,00822,032,040Oct 17 05:17 PM
Dolsten MikaelPresident R&DSep 13Option Exercise24.56181,7124,462,167234,299Sep 17 04:08 PM
OLSON LAURIE JExecutive Vice PresidentAug 13Sale41.0010,214418,77472,672Aug 14 05:04 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 03Sale39.5125,6421,013,171102,412Aug 06 03:19 PM
GOETTLER MICHAELGroup PresidentAug 01Sale39.7019,198762,11611,924Aug 03 03:38 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerAug 01Sale40.1626,8141,076,93383,846Aug 03 03:36 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentAug 01Sale40.0420,942838,5724,643Aug 03 03:35 PM
DAMELIO FRANK AExecutive Vice PresidentAug 01Sale40.00150,4846,019,360337,391Aug 03 03:33 PM
SUSMAN SALLYExecutive Vice PresidentJul 20Sale37.2240,3811,502,925115,096Jul 24 01:09 PM
READ IAN CChairman & CEOJul 16Sale37.36486,75318,186,315659,440Jul 17 04:59 PM
OLSON LAURIE JExecutive Vice PresidentJun 06Sale36.4519,000692,58282,886Jun 08 01:11 PM
CORNWELL W DONDirectorJun 04Sale36.405,223190,1170Jun 05 04:44 PM
READ IAN CChairman & CEOMay 01Sale36.01132,3124,764,0811,144,703May 03 04:19 PM
open in yahoo | open in reuters | open in google